- Home
- CGC vs XOMAP Comparison
CGC vs XOMAP Comparison
Compare CGC & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- XOMAP
- Stock Information
- Founded
- CGC N/A
- XOMAP N/A
- Country
- CGC Canada
- XOMAP United States
- Employees
- CGC N/A
- XOMAP 13
- Industry
- CGC Pharmaceuticals and Biotechnology
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- XOMAP Health Care
- Exchange
- CGC Nasdaq
- XOMAP Nasdaq
- Market Cap
- CGC 239.2M
- XOMAP N/A
- IPO Year
- CGC N/A
- XOMAP N/A
- Fundamental
- Price
- CGC $1.17
- XOMAP $25.88
- Analyst Decision
- CGC Sell
- XOMAP
- Analyst Count
- CGC 2
- XOMAP 0
- Target Price
- CGC $2.00
- XOMAP N/A
- AVG Volume (30 Days)
- CGC 9.4M
- XOMAP N/A
- Earning Date
- CGC 08-08-2025
- XOMAP N/A
- Dividend Yield
- CGC N/A
- XOMAP N/A
- EPS Growth
- CGC N/A
- XOMAP N/A
- EPS
- CGC N/A
- XOMAP N/A
- Revenue
- CGC $187,146,485.00
- XOMAP N/A
- Revenue This Year
- CGC $11.99
- XOMAP N/A
- Revenue Next Year
- CGC $6.84
- XOMAP N/A
- P/E Ratio
- CGC N/A
- XOMAP N/A
- Revenue Growth
- CGC N/A
- XOMAP N/A
- 52 Week Low
- CGC $0.77
- XOMAP N/A
- 52 Week High
- CGC $8.65
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- CGC 40.27
- XOMAP 48.21
- Support Level
- CGC $1.18
- XOMAP $25.64
- Resistance Level
- CGC $1.33
- XOMAP $26.05
- Average True Range (ATR)
- CGC 0.08
- XOMAP 0.10
- MACD
- CGC -0.00
- XOMAP -0.01
- Stochastic Oscillator
- CGC 4.55
- XOMAP 46.67
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.